-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $8

Benzinga·11/10/2026 13:56:17
Listen to the news
Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $10 to $8.